There was a significant association between high MUC16 expression in a cohort of 116 PDAC patients and altered receptor-tyrosine kinase (RTK) pathways, a highly upregulated and tumor-promoting mechanism in this cancer (Supplementary Figure S1C) [21,22]. Here, MUC16 is linked to cancer.